Small Business Innovation Research (SBIR)
The European Commission and The European Federation of Pharmaceutical Industries and Associations (EFPIA)
Leading venture capital firms focusing on life-science R&D according to FierceBiotech listing.
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2.5 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA. Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 220 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.
HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, project-focused companies with potential to transform patient care. HCV approach is to identify high potential products within academia or pharmaceutical companies, develop them to clinical proof-of-concept within capital efficient, semi-virtual organizations, and generate superior returns through acquisitions by pharmaceutical and biotechnology companies
Polaris Venture Partners
Polaris Venture Partners is a partnership of experienced venture capital investors and technology executives. Our mission is to identify and invest in seed, first round, and early stage technology and life science businesses with exceptional promise and help them grow into sustainable, market-leading companies. In addition, Polaris is committed to providing growth equity and shareholder liquidity to established companies in the technology, healthcare, manufacturing, media, communications, and business services sectors. As a national venture capital firm with offices in the high-tech centers of Boston and Seattle, we’re able to invest in businesses throughout the United States and around the world. The firm has over $3 billion under management and current investments in more than 100 companies.
MPM Capital is one of the world’s largest life science-dedicated venture investors. With committed capital under management in excess of $2 billion, MPM Capital is uniquely structured to invest globally in healthcare innovation.
Alta Partners is a leading venture capital firm in life sciences, funding over 130 companies in the industry since 1996. The diverse and integrated team brings together a powerful depth of knowledge and experience, delivering tangible results for our companies and our investors.
Alta is committed to building successful businesses through deep collaborative partnerships with outstanding entrepreneurs. Alta invests only in those areas where it has specific domain expertise.
ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences, physical sciences, and information technology. The firm enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories.
Flagship Ventures is a venture capital firm focused on creating, financing and building innovative companies. Founded in 2000, Flagship manages over $600 million in early-stage funds and operates from its offices at Kendall Square in Cambridge, MA. With an active portfolio of over 40 companies, the firm’s strategy is to balance its investments across three principal business sectors: Therapeutics, Life Science Tools & Diagnostics, and BioEnergy/Cleantech.
SV Life Sciences
SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SVLS team manages six venture capital funds and a publicly traded investment trust with approximately $2 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco.
Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies. Sanderling demonstrates that significant companies are best built in close working partnerships with entrepreneurs. Sanderling’s unique approach combines a specialized investment focus with active management and long-term commitment to ensure the highest rates of return for both its entrepreneurs and investors. Biomedical investing has been a viable sector in the technology markets for more than thirty years, and in the past ten years has experienced accelerated growth. Since its inception, Sanderling has supported over 90 biomedical companies from very early stage start-ups, through commercial development, earning consistently high rates of return on its venture investments.
Kleiner Perkins Caufield & Byers
Kleiner Perkins Caufield & Byers are passionately committed to helping their portfolio companies succeed. Entrepreneurs gain access to their matched portfolio of companies and associations with global business leaders. These relationships are the foundation for strategic alliances, partnership opportunities and the sharing of insights to help build new ventures faster, broader and with less risk.
For more than 30 years InterWest has partnered with exceptional entrepreneurs to build winning technology and life sciences companies. With more than 200 years of combined operating and investing experience, our team has raised $2.8B, completed more than 70 IPOs, and participated in nearly 60 upside acquisitions. As we invest InterWest X, a $650M fund, Partners continue to believe that providing capital is just the beginning of a long-term collaboration with entrepreneurs to turn their vision into a thriving company.
Sofinnova Ventures has over 30 years of experience building start-ups and spin-outs into market leaders. With $1 billion under management, the firm applies capital and expertise to guide early stage companies to successful exits.
Burrill Venture Capital
The Burrill family of venture capital funds includes funds with more than $950 million under management. These funds were formed to capitalize on Burrill’s unique investment platform and the opportunities created by today’s intersection of the genomic/proteomic and biologic revolution, and capital market inefficiency occurring within the life science field.
New Enterprise Associates
For more than 30 years, NEA has been helping to build great companies. NEA’s committed capital has grown to $11 billion and it’s funded more than 650 companies in the Information Technology, Energy Technology and Healthcare sectors. With more than 65 investment professionals working out of offices in the US, India, and China and investing across the globe—NEA is the entrepreneur’s venture capital firm, consistently ranking among the top firms in portfolio IPOs each year. Since its founding, the firm has backed more than 165 companies that have gone public and invested in more than 255 companies that have been successfully merged or acquired—more liquidity events than any other venture capital firm.
OrbiMed is the world’s largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed’s investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds. OrbiMed’s investment team includes over 35 experienced professionals with backgrounds in science, medicine, industry, finance, information technology and law.
Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads investments across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services. Quaker BioVentures invests in companies at all stages of development, from early stage start-ups to public companies. Founded in 2003, the firm is currently investing Quaker BioVentures II, a $420 million fund formed in 2007. Quaker BioVentures manages over $700 million in committed capital.
Venrock was founded in 1969 as the venture capital arm of the Rockefeller Family and we have $2.2 billion under management. Venrock provides funding and services for entrepreneurs with breakthrough ideas in technology, healthcare, media and energy. Venrock’s entrepreneurs have charted new advancements in cancer and HIV treatments, powered semiconductors and the digital era, secured our information technology infrastructure, pioneered on-line advertising, delighted consumers and most recently, generating power through alternative means. Venrock’s 22 investment professionals currently back 117 ventures out of offices in Palo Alto, New York City, Cambridge, and Israel.
More venture companies:
Alliance Technology Ventures
Apple Tree Partners
Edmond de Rothschild Investment Partners
Bay City Capital
Bessemer Venture Partners
Caxton Advantage Life Sciences Fund
Chicago Growth Partners
Devon Park Bioventures
Enterprise Partners Venture Capital
Essex Woodlands Health Ventures
Excel Medical Fund
Frazier Healthcare Ventures
Grupo Cornelio Brennand
Highland Capital Partners
McNerney & Partners
MDV-Mohr Davidow Ventures
MVM Life Science Partners
OVP Venture Partners
Oxford Finance Corporation
Prospect Venture Partners
Rho Capital Partners
Scale Venture Partners
Sectoral Asset Management
SR One, the corporate venture fund of GlaxoSmithKline
Sutter Hill Ventures
Teachers’ Private Capital
The Column Group
Votorantim Novos Negocios
Ysios Capital Partners